Journal Article Epublish
PubMed: 40266114 DOI: 10.3390/vaccines13030244
Assessment of COVID-19 Vaccine Effectiveness Against SARS-CoV-2 Infection, Hospitalization and Death in Mexican Patients with Metabolic Syndrome from Northeast Mexico: A Multicenter Study.
Vaccines (Basel) 13(3)
Authors: Beatriz Silva Ramírez, Katia Peñuelas Urquides, Brenda Leticia Escobedo Guajardo, Viviana Leticia Mata Tijerina, Jorge Eleazar Cruz Luna, Roberto Corrales Pérez, Salvador Gómez García, Laura Adiene González Escalante, María Elena Camacho Moll
Affiliations
- Laboratory of Immunogenetics, Northeast Biomedical Research Center, Mexican Social Security Institute, Monterrey 64720, Nuevo Leon, Mexico.
- Laboratory of Molecular Microbiology, Northeast Biomedical Research Center, Mexican Social Security Institute, Monterrey 64720, Nuevo Leon, Mexico.
- Laboratory of Molecular Research of Diseases, Northeast Biomedical Research Center, Mexican Social Security Institute, Monterrey 64720, Nuevo Leon, Mexico.
- Medical Epidemiological Assistance Coordination of the State of Nuevo Leon, Mexican Social Security Institute, Monterrey 64000, Nuevo Leon, Mexico.
- Laboratory of Molecular Biology, Northeast Biomedical Research Center, Mexican Social Security Institute, Monterrey 64720, Nuevo Leon, Mexico.
Abstract
Metabolic syndrome (MetS) is a predisposing factor for severe COVID-19. The effectiveness of COVID-19 vaccines in patients with MetS has been poorly investigated. The aim of this study was to evaluate the effectiveness of COVID-19 vaccination before (BO) and after the Omicron (AO) SARS-CoV-2 variant in patients with MetS. This retrospective observational study was carried out in a total of 3194 patients with MetS and a COVID-19 PCR or rapid antigen test. The main outcomes were vaccine effectiveness against infection, hospitalization and death resulting from COVID-19. BO, only two doses of BNT162b2 were effective against infection, this effectiveness was lost AO. Also, with two doses, BNT162b2, ChAdOx1 and CoronaVac were effective against hospitalization BO; however, AO, only BNT162b2 and CoronaVac were effective. Regarding death as an outcome of COVID-19, two doses of BNT162b2 were effective BO, whereas AO, BNT162b2 and CoronaVac were 100% effective. BO the presentation of a sore throat increased after two doses of COVID-19 vaccine regardless of the type, and the presentation of dyspnea diminished after two doses of BNT162b2 and CoronaVac. The SARS-CoV-2 Omicron variant has impacted vaccines' effectiveness against hospitalization and death in patients with MetS. A tailored vaccination scheme for patients with MetS should be implemented due to the varying effectiveness rates observed in our study.
MeSH
Sars-Cov-2, Hospitalization, Vaccines, Covid-19 Vaccines, Vaccination, Covid-19, Severe Acute Respiratory Syndrome-Related Coronavirus, Metabolic Syndrome, Infections, Vaccine Efficacy